• Exchange: EN Brussels
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

ThromboGenics NV

+ Add to Watchlist


9.6900 EUR 0.3600 3.58%

As of 06:05:26 ET on 07/25/2014.

Snapshot for ThromboGenics NV (THR)

Open: 10.1750 Day's Range: 9.4500 - 10.1750 Volume: 67,480
Previous Close: 10.0500 52wk Range: 7.9000 - 32.8300 1-Yr Rtn: -68.88%

Stock Chart for THR

No chart data available.
  • THR:BB 9.6900
  • 1D
  • 1M
  • 1Y
Interactive THR Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for THR

Current P/E Ratio (ttm) 13.8356
Estimated P/E(12/2014) -
Relative P/E vs. BEL20 0.2674
Earnings Per Share (EUR) (ttm) 0.7300
Est. EPS (EUR) (12/2014) -1.3930
Est. PEG Ratio -
Market Cap (M EUR) 364.55
Shares Outstanding (M) 36.09
30 Day Average Volume 302,682
Price/Book (mrq) 1.3516
Price/Sale (ttm) 3.0875
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/28/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for THR

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)

Company Profile & Key Executives for THR

ThromboGenics NV is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company is focused on developing medicines to treat visual disorders, cardiovascular diseases, and cancer, conditions which result from abnormalities to the vascular system.

Gustaaf Van Reet "Staf"ChairmanPatrik De HaesCEO/Executive Director
Luc PhilipsInterim CFOKoen KasChief Scientific Officer
More Company Profile & Key Executives for THR

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil